What is Mirvie?
Founded in 2018, Mirvie is a South San Francisco-based biotechnology firm dedicated to improving pregnancy outcomes. The company addresses a significant unmet need in the healthcare sector, where one in five pregnancies is impacted by complications that can lead to long-term health consequences. Mirvie's core innovation is a non-invasive blood test that utilizes RNA sequencing to reveal the unique biology of a pregnancy, allowing clinicians to intervene months before clinical symptoms manifest. By shifting the paradigm from reactive to proactive care, Mirvie is establishing a new category in women's health, supported by a team of scientists and entrepreneurs with a proven track record in diagnostic innovation.
How much funding has Mirvie raised?
Mirvie has raised a total of $89.5M across 3 funding rounds:
Angel/Seed
$5.8M
Series B
$60M
Private Equity
$23.7M
Angel/Seed (2018): $5.8M with participation from Khosla Ventures
Series B (2022): $60M led by Decheng Capital, Foresite Capital, Comerica, GV, General Catalyst, Mayfield, Khosla Ventures, and BlackRock
Private Equity (2025): $23.7M, investors not publicly disclosed
Key Investors in Mirvie
Decheng Capital
Decheng Capital is a global investment firm specializing in providing capital and strategic support to early-stage life science companies and growth-stage healthcare enterprises.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
GV
GV is a venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
What's next for Mirvie?
With this major enterprise-level funding, Mirvie is well-positioned to accelerate its clinical development and expand the reach of its diagnostic platform. The strategic capital will likely be deployed to scale operations, enhance the sensitivity of its RNA-based detection models, and broaden its commercial footprint. As the company moves through its current lifecycle stage, the focus will remain on securing regulatory milestones and integrating its technology into standard prenatal care workflows. By maintaining its commitment to rigorous scientific validation and strategic partnerships, Mirvie aims to solidify its market position as a leader in predictive pregnancy health, ultimately reducing the incidence of preventable complications for expecting parents globally.
See full Mirvie company page
